DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
Loading...
  • Stocks
  • /
  • Pharmaceuticals & Biotech
Updated 1d ago
A058820 logo

CMG Pharmaceutical Co., Ltd.KOSDAQ:A058820 Stock Report

Market Cap ₩84.3b
Updated 1d ago
Share Price
n/a
1Y-69.4%
7D-5.2%
1D0.5%
Portfolio Value
​
View

CMG Pharmaceutical Co., Ltd.

KOSDAQ:A058820 Stock Report

Market Cap: ₩84.3b

  • Company Overview
    • Valuation
    • Future Growth
    • Past Performance
    • Financial Health
    • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

CMG Pharmaceutical (A058820) Stock Overview

A pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. More details

A058820 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance1/6
Financial Health3/6
Dividends0/6

Rewards

Became profitable this year

Risk Analysis

High level of non-cash earnings

Earnings have declined by 60.4% per year over past 5 years

Does not have a meaningful market cap (₩84B)


A058820 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW429,412 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
429,412 investors already sharing narratives
₩
Current Price
₩569.0045.3% overvalued intrinsic discount
%/yr
Decrease
Increase
PastFuture-18b116b2016201920222025202620282031Revenue ₩115.7bEarnings ₩4.6b
Advanced
View all narratives

CMG Pharmaceutical Co., Ltd. Competitors

DongKoo Bio & Pharma

Symbol: KOSDAQ:A006620
Market cap: ₩94.9b

Theragen EtexLtd

Symbol: KOSDAQ:A066700
Market cap: ₩78.1b

Sinsin Pharmaceutical

Symbol: KOSDAQ:A002800
Market cap: ₩68.1b

Daehan NupharmLtd

Symbol: KOSDAQ:A054670
Market cap: ₩77.9b

Price History & Performance

Summary of share price highs, lows and changes for CMG Pharmaceutical
Historical stock prices
Current Share Price₩569.00
52 Week High₩2,205.00
52 Week Low₩526.00
Beta0.44
1 Month Change-5.32%
3 Month Change-43.50%
1 Year Change-69.43%
3 Year Change-76.09%
5 Year Change-86.52%
Change since IPO-75.04%

Recent News & Updates

Analysis Article • Jan 28

Does CMG Pharmaceutical (KOSDAQ:058820) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Nov 28

CMG Pharmaceutical Co., Ltd.'s (KOSDAQ:058820) Business Is Yet to Catch Up With Its Share Price

When you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...

Recent updates

Analysis Article • Jan 28

Does CMG Pharmaceutical (KOSDAQ:058820) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Nov 28

CMG Pharmaceutical Co., Ltd.'s (KOSDAQ:058820) Business Is Yet to Catch Up With Its Share Price

When you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...
Analysis Article • Mar 26

Is CMG Pharmaceutical (KOSDAQ:058820) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Nov 20

There May Be Reason For Hope In CMG Pharmaceutical's (KOSDAQ:058820) Disappointing Earnings

The market for CMG Pharmaceutical Co., Ltd.'s ( KOSDAQ:058820 ) shares didn't move much after it posted weak earnings...
Analysis Article • Mar 27

CMG Pharmaceutical's (KOSDAQ:058820) Solid Earnings Are Supported By Other Strong Factors

CMG Pharmaceutical Co., Ltd. ( KOSDAQ:058820 ) just reported healthy earnings but the stock price didn't move much. We...
Analysis Article • Dec 28

Did You Participate In Any Of CMG Pharmaceutical's (KOSDAQ:058820) Fantastic 203% Return ?

It's been a soft week for CMG Pharmaceutical Co., Ltd. ( KOSDAQ:058820 ) shares, which are down 13%. But that doesn't...

Shareholder Returns

A058820KR PharmaceuticalsKR Market
7D-5.2%-0.5%-0.1%
1Y-69.4%-19.7%89.2%

Return vs Industry: A058820 underperformed the KR Pharmaceuticals industry which returned -19.7% over the past year.

Return vs Market: A058820 underperformed the KR Market which returned 89.2% over the past year.

Price Volatility

Is A058820's price volatile compared to industry and market?
A058820 volatility
A058820 Average Weekly Movement10.5%
Pharmaceuticals Industry Average Movement6.8%
Market Average Movement8.9%
10% most volatile stocks in KR Market16.3%
10% least volatile stocks in KR Market4.2%

Stable Share Price: A058820 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A058820's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001242Joohyung Leewww.cmgpharma.co.kr

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd.

CMG Pharmaceutical Co., Ltd. Fundamentals Summary

How do CMG Pharmaceutical's earnings and revenue compare to its market cap?
A058820 fundamental statistics
Market cap₩84.28b
Earnings (TTM)₩4.64b
Revenue (TTM)₩115.71b
18.2x
P/E Ratio
0.7x
P/S Ratio

Is A058820 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A058820 income statement (TTM)
Revenue₩115.71b
Cost of Revenue₩51.23b
Gross Profit₩64.48b
Other Expenses₩59.84b
Earnings₩4.64b

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)31.33
Gross Margin55.72%
Net Profit Margin4.01%
Debt/Equity Ratio33.5%

How did A058820 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/19 14:51
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CMG Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide